EMEA-000980-PIP01-10-M07
Key facts
Invented name |
Adcetris
|
Active substance |
Brentuximab vedotin
|
Therapeutic area |
Oncology
|
Decision number |
P/0013/2021
|
PIP number |
EMEA-000980-PIP01-10-M07
|
Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Takeda Pharma A/S
Tel. +45(0) 46771111 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-000980-PIP01-10-M07
|
Compliance opinion date |
25/06/2021
|
Compliance outcome |
positive
|